Inactive Instrument

AXCA HEALPAR

Equities

AXLA

US05454B2043

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
North American Morning Briefing : S&P 500 Eyes Record High as Rate Cut Hopes Underpin Sentiment DJ
North American Morning Briefing : Traders Eye -2- DJ
North American Morning Briefing : China Outlook Downgrade Jolts Mood DJ
North American Morning Briefing : November Rally Pauses Ahead of This Week's PCE Report DJ
Axcella Health Inc.(NasdaqGM:AXLA) dropped from S&P TMI Index CI
Axcella Health Inc.(OTCPK:AXLA) dropped from NASDAQ Composite Index CI
North American Morning Briefing : All Eyes on -2- DJ
Investors Look Forward to Fed Minutes, Economic Data as Exchange-Traded Funds, Equity Futures Rise Marginally Pre-Bell MT
Top Premarket Decliners MT
Axcella Health Inc. Announces Chief Executive Officer Changes CI
Axcella Health Inc. Appoints Craig R. Jalbert as Principal Financial Officer CI
Axcella Health Inc. Announces Management Changes CI
Axcella Health Sinks Premarket Wednesday, Shares Poised for Ninth Decline in 10 Days Following Reverse Stock Split MT
Axcella Health Slips Premarket Friday, Poised for Seventh Consecutive Day of Declines After Announcing Reverse Stock Split MT
Correction: --Axcella Health Slumped 8.1% in Premarket Activity Thursday After Sinking 15% in Previous Regular Trading Session MT
Axcella Health Slumped 8.1% in Premarket Activity Wednesday After Sinking 15% in Previous Regular Trading Session MT
Top Midday Decliners MT
Axcella Health to Implement 1-for-25 Reverse Stock Split -- Shares Dive After-Hours MT
Sector Update: Health Care Stocks Rising Late Afternoon MT
Sector Update: Health Care MT
Top Midday Gainers MT
Axcella Health Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Axcella Health Inc. Announces Resignation of Margaret Koziel as Senior Vice President and Chief Medical Officer CI
Axcella Health Inc.(NasdaqGM:AXLA) dropped from Russell Microcap Index CI
Axcella Health Inc.(NasdaqGM:AXLA) dropped from Russell Microcap Growth Index CI
Chart AXCA HEALPAR
More charts
Axcella Health Inc. is a clinical-stage biotechnology company. The Company is focused on a new approach to treat complex diseases using compositions of endogenous metabolic modulators (EMMs). Its product candidates are comprised of multiple EMMs that are engineered in distinct combinations and ratios with simultaneously impacting multiple biological pathways. Its pipeline includes lead therapeutic candidates for the treatment of Long COVID (also known as Post-COVID-19 Condition and Post-Acute Sequelae of COVID-19 (PASC)) associated fatigue, and the treatment of non-alcoholic steatohepatitis (NASH). AXA1665 is a product candidate for the reduction in risk of Overt Hepatic Encephalopathy (OHE) recurrence in adult patients with liver cirrhosis. AXA1125 is also being developed as a product candidate for the treatment of Long COVID. AXA1125 is an oral product candidate for the treatment of NASH. AXA1125 is an oral product candidate that contains six amino acids and derivatives.
Sector
-
More about the company
  1. Stock
  2. Equities
  3. Stock AXCA HEALPAR - OTC Markets
  4. News AXCA HEALPAR
  5. Axcella Health : HC Wainwright Starts Axcella Health at Buy With $14 Price Target